LSM1 and familial pancreatic carcinoma: Our laboratory group previously identified CaSm as an oncogene whose overexpression is necessary for cellular transformation in pancreatic cancer and which has potential as a therapeutic target enhancing gemcitabine therapy.14, 16, 17, 28 A more specific understanding of CaSm's position in the development of PC remained largely unknown.